Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 783-795

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM ANTAGONIST; COCAINE; DIHYDROPYRIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOCORTICOID; GLYCERYL TRINITRATE; GLYCYRRHIZA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LOOP DIURETIC AGENT; METHYLDOPA; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ALCOHOL CONSUMPTION; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDITORIAL; EUROPE; FAMILY HISTORY; FOLLOW UP; GERIATRIC PATIENT; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOME MONITORING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREECLAMPSIA; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; SODIUM RESTRICTION; WEIGHT REDUCTION; WOMEN'S HEALTH;

AGE FACTORS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEX FACTORS; SOCIETIES, MEDICAL;

EID: 38149056428     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (91)

1. Amar J, Chamontin B, Genes N, et al. 2003. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens, 21:1199-205.
2. Ambrosioni E. 2001. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens, 19(Suppl 3):S33-40.
3. Arima H, Chalmers J, Woodward M, et al. 2006. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens, 24:1201-8.
4. Asia Pacific Cohort Studies Collaboration. 2005. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation, 112:3384-90.
5. Assmann G Schulte H. 1988. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J, 116:1713-24.
6. Blacher J, Staessen JA, Girerd X, et al. 2000. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med, 160:1085-9.
7. Bobrie G, Chatellier G, Genes N, et al. 2004. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA, 291:1342-9.
8. Burt VL, Cutler JA, Higgins M, et al. 1995. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US po pulation. Data from the Health Examination Surveys, 1960 to 1991. Hypertension, 26:60-9.
9. Collins R, Peto R, MacMahon S, et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335:827-39.
10. Collins R, MacMahon S. 1994. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull, 50:272-98.
11. Criqui MH, Langer RD, Fronek A, et al. 1992. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med, 326:381-6.
12. Dekker JM, Girman C, Rhodes T, et al. 2005. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoom Study. Circulation, 112:666-73.
13. Dickerson JE, Hingorani AD, Ashby MJ, et al. 1999. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet, 353:2008-13.
14. Dickinson HO, Mason JM, Nicolson DJ, et al. 2006. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomised controlled trials. J Hypertens, 24:215-33.
15. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 360:752-60.
16. Doll R, Peto R, Wheatley K, et al. 1994. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J, 309:901-11.
17. Domanski MJ, Mitchell GF, Norman JE, et al. 1999. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol, 33:951-8.
18. Dunder K, Lind L, Zethelius B, et al. 2003. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Br Med J, 326:681.
19. ESH/ESC Hypertension Practice Guidelines Committee. 2003. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens, 21:1779-86.
20. ESH/ESC Hypertension Practice Guidelines Committee. 2007. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens, 25:1105-87.
21. Ezzati M, LopezAD, Rodgers A, et al. 2002. Selected major risk factors and global and regional burden of disease. Lancet, 360:1347-60.
22. Fagard RH, Staessen JA, Thijs L, et al. 2000. Response to antihypertensive treatment in older patients with sustained or nonsustained systolic hypertension. Circulation, 102:1139-44.
23. Fagard RH. 2001. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc, 33:S484-92.
24. Fagard RH, Celis H. 2004. Prognostic significance of various characteristics of out-of-the-office blood pressure. J Hypertens, 22:1663-6.
25. Fagard RH, Van Den Broeke C, De Cort P. 2005a. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens, 19:801-07.
26. Fagard RH, Bjomstad HH, Bodesson M, et al. 2005b. ESC Study Group of Sports Cardiology recommendations for participation in leisure-time physical activities andcompetitive sports for patients with hypertension. Eur J Cardiovasc Prev Rehabil, 12:326-31.
27. Freemantle N, Cleland J, Young P, et al. 1999. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 318:1730-7.
28. Gasowski J, Fagard RH, Staessen JA, et al. 2002. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens, 20:145-51.
29. Girman CJ, Rhodes T, Mercuri M, et al. 2004. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol, 93:136-41.
30. Haffner SM, Lehto S, Ronnemaa T, et al. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339:229-34.
31. Hansen TW, Jeppesen J, Rasmussen S, et al. 2006. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens, 19:243-50.
32. Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351:1755-62.
33. Haynes RB, McDonald HP, Garg AX. 2002. Helping patients follow prescribed treatment: clinical applications. JAMA, 288:2880-3.
34. Jennings GL. 1997. Exercise and blood pressure: Walk, ran or swim? J Hypertens, 15:567-9.
35. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Report: a cooperative study. 1977. JAMA, 237:255-61.
36. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. 1980. The 1980 Report. Arch Intern Med, 140:1280-5.
37. Kannel WB. 1996. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA, 275:1571-6.
38. Kannel WB, Wolf PA, Benjamin EJ, Levy D. 1998. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol, 82:2N-9N.
39. Kannel WB. 2000. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens, 13(Suppl 1):S3-S10.
40. Kearney PM, Whelton M, Reynolds K, et al. 2005. Global burden of hypertension: analysis of worldwide data. Lancet, 365:217-23.
41. Khattar RS, Senior R, Lahiri A. 1998. Cardiovascular outcome in white-coat versus sustained mild hypertension. A 10-year follow-up study. Circulation, 98:1892-7.
42. Kilander L, Nyman H, Boberg M, et al. 1998. Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension, 31:780-6.
43. Klag MJ, Whelton PK, Randall BL, et al. 1996. Blood pressure and end-stage renal disease in men. N Engl J Med, 334:13-8.
44. Knowler WC, Sartor G, Melander A, Schersten B. 1997. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia, 40:680-6.
45. Lakka HM, Laaksonen DE, Lakka TA, et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288:2709-16.
46. Launer LJ, Masaki K, Petrovitch H, et al. 1995. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA, 274:1846-51.
47. Laurent S, Cockcroft J, Van Bortel L, et al. 2006. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J, 27:2588-05.
48. Law MR. 1997. Epidemiologic evidence on salt and blood pressure. Am J Hypertens, 10(Suppl 5):S42-5.
49. Lee VC, Rhew DC, Dylan M, et al. 2004. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med, 141:693-704.
50. Levy D, Larson MG, Vasan RS, et al. 1996. The progression from hypertension to congestive heart failure. JAMA, 275:1557-62.
51. MacMahon S, Peto R, Cutler J, et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335:765-74.
52. Mancia G, Ambrosioni E, Agabiti-Rosei E, et al. 2005. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens, 23:1575-81.
53. Mancia G, Parati G, Borghi C, et al. 2006a. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens, 24:837-43.
54. Mancia G, Facchetti R, Bombelli M, et al. 2006b. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension, 47:846-53.
55. Mancia G, Bombelli M, Corrao G, et al. 2007a. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension, 49:40-7.
56. Mancia G, Bousquet P, Elghozi JL, et al. 2007b. The sympathetic nervous system and the metabolic syndrome. J Hypertens, in press.
57. Manson JE, Tosteson H, Ridker PM, et al. 1992. The primary prevention of myocardial infarction. N Engl J Med, 326:1406-16
58. Martiniuk AL, Lee CM, Lawes CM, et al. 2007. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens, 25:73-9.
59. Morgan TO, Anderson Al, MacInnis RJ. 2001. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens, 14:241-7.
60. Mule G, Nardi E, Cottone S, et al. 2005. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med, 257:503-13.
61. Multiple Risk Factor Intervention Trial Research Group. 1986. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med, 15:254-73.
62. Nides M, Oncken C, Gonzales D, et al. 2006. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med, 166:1561-8.
63. Ohkubo T, Kikuya M, Metoki H, et al. 2005. Prognosis of masked hypertension and white-coat hypertension detected by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol, 46:508-15.
64. PATS Collaborative Group. 1995. Post-stroke antihypertensive treatment study. Chin Med J, 108:710-7.
65. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. 2003. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349:1893-6.
66. PROGRESS Collaborative Study Group. 2001. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet, 358:1033-41.
67. Prospective Studies Collaboration. 2002. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-13.
68. Puddey IB, Beilin LJ, Rakie V. 1997. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol, 2:159-70.
69. Resnick HE, Jones K, Ruotolo G, et al. 2003. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care, 26:861-7.
70. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. 1985. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med, 313:1511-4.
71. Sacks FM, Svetkey LP, Vollmer WM, et al. 2001. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med, 344:3-10.
72. Sandvik L, Erikssen. J, Thaulow E, et al. 1993. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med, 328:533-7.
73. Schmidt MI, Duncan BB, Bang H, et al. 2005. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care, 28:2013-8.
74. Shekelle PG, Rich MW, Morton SC, et al. 2003. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol, 41:1529-38.
75. Silagy C, Mant D, Fowler G, Lodge M. 1994. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet, 343:139-42.
76. Skoog I, Lernfelt B, Landahl S, et al. 1996. 15-year longitudinal study of blood pressure and dementia. Lancet, 347:1141-5.
77. Staessen JA, Gasowski J, Wang JG, et al. 2000. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet, 355:865-72.
78. Stamler J, Vaccaro O, Neaton JD, Wentworth D. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-44.
79. Stringer WW, Wasserman K. 2005. Statement on exercise: American College of Chest Physicians/American Thoracic Society-exercise for fun or profit? Chest, 127:1072-3.
80. Thomas F, Rudnichi A, Bacri AM, et al. 2001. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension, 37:1256-61.
81. Tonstad S, Farsang C, Klaene G, et al. 2003. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J, 24:946-55.
82. Vasan RS, Larson MG, Leip EP, et al. 2001a. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet, 358:1682-6.
83. Vasan RS, Larson MG, Leip EP, et al. 2001b. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med, 345:1291-7.
84. Vasan RS, Beiser A, Seshadri S, et al. 2002. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA, 287:1003-10.
85. Verdecchia P, Reboldi GP, Angeli F, et al. 2005. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension, 45:203-8.
86. Wannamethee SG, Shaper AG. 1996. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke, 27:1033-9.
87. Wei M, Mitchell BD, Haffiler SM, Stem MP. 1996. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all-cause mortality and cardiovascular disease mortality in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol, 144:1058-65.
88. WHO/FAO. 2003. Joint WHO/FAO Expert report on diet, nutrition and the prevention of chronic disease. Executive Summary [online]. Accessed 15 July 2007. URL: http://www.who.int/dietphysicalactivity/publications/ trs916/summary/en/index.html.
89. Wolf-Maier K, Cooper RS, Banegas JR, et al. 2003. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA, 289:2363-9.
90. Yap YG, Duong T, Bland JM, et al. 2007. Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. J Hypertens, 25:307-13.
91. Zanchetti A, Hansson L, Menard J, et al. 2001. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. J Hypertens, 19:819-25.